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Depressive disorders are present in about 10% of pri-
mary care patients and account for more years lived with
disability than any single disease.1,2 Nearly three-quarters
of all outpatient visits for
depression are to primary
care clinicians rather than to
mental health specialists.3
Collaborative care is a therapeutic intervention in which
behavioral health is integrated into primary care, most com-
monly using a nurse care manager to monitor depressive
symptoms in depressed patients and adjust treatment
under the supervision of a psychiatrist. Many of the nurse
contacts are conducted by telephone, thereby increasing the
efficiency of collaborative care. Although collaborative care
has been demonstrated to improve depression in more than
80 randomized clinical trials,4,5 most trials have targeted
major depression.
Major depression requires the presence of at least 5
of 9 criterion symptoms of depression for 2 weeks or
longer, with at least 1 of the symptoms being depressed
mood or anhedonia.6 In comparison, subthreshold depres-
sion (also called minor or subsyndromal depression) is
the presence of 2 to 4 criterion symptoms of depression for
2 weeks or longer with at least 1 of the core symptoms
(depressed mood or anhedonia).6,7 Alternative definitions
of subthreshold depression use a severity cut point on a
depression scale or vary in duration and core symptom
requirements but typically require the absence of major
depression. Only a small number of therapeutic trials have
targeted subthreshold depression, and results have been
mixed.6,8 Identifying effective therapies for subthreshold
depression is important because many patients with sub-
threshold depression have persistent depressive symptoms
at 12-month follow-up, a third to half report moderate func-
tional impairment, and at least 10% to 20% progress to major
depression.6,7,9,10
In this issue of JAMA, the CASPER trial by Gilbody et al11
provides the first evidence that collaborative care may ben-
efit patients with subthreshold depression. In this prag-
matic clinical trial conducted in the United Kingdom, the
authors randomized 705 adults aged 65 years or older with
subthreshold depression to either a collaborative care inter-
vention or usual primary care. The collaborative care treat-
ment consisted of 8 weekly 30-minute sessions of behav-
ioral activation administered by a care manager with a
background in mental health nursing or psychology who
was supervised by a mental health professional. Behavioral
activation is a psychological intervention that encourages
increased social interactions and engagement in pleasur-
able, rewarding activities. The first session was face-to-face,
and subsequent sessions were delivered by telephone.
Several important findings emerged from the CASPER
trial. First, improvement on the 9-item Patient Health Ques-
tionnaire depression score (PHQ-9, which ranges from 0-27)
at 4 months was 1.3 points greater in the collaborative care
group compared with the usual care group (the PHQ-9 score
was 7.8 in both groups at baseline and declined to 5.4 in the
collaborative care group and 6.7 in the usual care group).
This difference was sustained at 12-month follow-up and
represents an effect size of 0.3, consistent with a small to
moderate clinical improvement and comparable with the
average effect size demonstrated in collaborative care trials
for major depression.4,5 This is notable because the mean
baseline PHQ-9 score among patients in this trial was only
7.8 (median, 7), meaning that there was a limit to howmuch
improvement could be achieved given that a score of less
than 5 corresponds to minimal depressive symptoms.
A second important finding was that progression to
threshold-level depression (defined in this trial as a PHQ-9
score ≥10) was not different between the 2 groups at 4
months (17.2% vs 23.5%) but was significantly less frequent
in the collaborative care group compared with usual care at
12 months (15.7% vs 27.8%). This represents a relative risk of
0.65 (95% CI, 0.46-0.91). Third, the collaborative care inter-
vention improved anxiety, functional status, and several
other secondary outcomes compared with usual care. The
effect size for anxiety was 0.23 at 4-month follow-up, a sig-
nificant between-group difference that was sustained at
12-month follow-up and comparable with the average effect
sizes of 0.30 to 0.33 reported in other studies examining
collaborative care for anxiety.4,5 The reduction in anxiety is
especially important because anxiety has a similar preva-
lence as depression in primary care practice and is present
in a third to half of patients with depression.1
Another important aspect of the CASPER intervention
was that it was brief and relatively inexpensive. The inter-
vention consisted of 8 telephone sessions lasting 30 min-
utes each delivered by care managers with less psychologi-
cal training than psychologists or other mental health
professionals. Other study strengths included the large
sample size; the low rate of antidepressant therapy, which
was balanced among groups (thus minimizing the effect of
antidepressants as a cointervention and potential con-
founder); and a sensitivity analysis showing that effective-
ness did not vary among care managers. Although attrition
was higher in the collaborative care group than in the usual
care group, imputed analyses accounting for this difference
did not change the results.
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The core treatment in the CASPER trial was behavioral
activation, for which a previous meta-analysis of 26 trials
involving 1524 depressed patients also showed a reduction
in depression.12 Strong evidence for the effectiveness of
behavioral activation was provided by the recent COBRA
trial, in which 440 adults with major depression were ran-
domized to either behavioral activation or cognitive behav-
ioral therapy.13 Each group received an average of 12 one-
hour in-person sessions, and behavioral activation was
found to be noninferior to cognitive behavioral therapy for
the outcome of depression. A meta-analysis of brief psycho-
logical therapies (typically ≤8 sessions) found that cognitive
behavioral therapy (13 trials), problem-solving therapy
(12 trials), and counseling (8 trials) were all associated with
improved depression outcomes in primary care, with effect
sizes ranging from 0.21 to 0.33.14 Thus, behavioral activa-
tion can now be added to the list of brief therapies that
might be considered for treating depressed patients in pri-
mary care.
A recent German trial also found benefits in treating
subthreshold depression: 406 adults with subthreshold
depression were randomized to either a web-based guided
intervention (cognitive behavioral and problem-solving
therapy supported by an online trainer) or a web-based psy-
choeducation control program.15 Fewer patients in the inter-
vention group progressed to major depression at 12-month
follow-up (27% vs 41%), resulting in a number needed to
treat of 5.9 to avoid 1 new case of major depression (com-
pared with a number needed to treat of 8.3 in CASPER). Cost-
effectiveness results for the CASPER trial are planned but not
yet available. Notably, collaborative care interventions for
major depression are cost-effective for the outcome of
quality-adjusted life-years.5,16 Whether this is also true for
collaborative care interventions that target subthreshold
depression, for which the absolute amount of improvement
is less, needs to be evaluated.
Do results of these recent trials mean that clinicians
should expand therapy beyond major depression to include
active treatment of subthreshold depression? There are sev-
eral factors to consider. First, the way in which subthreshold
depression is defined varies across studies.7 The lack of a
consensus on the definition of subthreshold depression can
complicate comparisons across treatment trials that define
subthreshold depression differently.
Second, the rate at which subthreshold depression pro-
gresses to major depression varies. Although the progression
rate in the control groups of the CASPER and German trials
ranged from 28% to 41% over 12 months,11,15 other studies
suggest a lower progression rate of 10% to 20%.6,9 The higher
progression rates in the CASPER and German studies may be
because trial participants had a moderate degree of func-
tional impairment. Previous research has shown that the sub-
group of patients with subthreshold depression and func-
tional impairment is the most likely to benefit from active
treatment.6,17 It is likely that if all patients with subthreshold
depression were actively treated regardless of level of impair-
ment, the magnitude of benefit would be less and the num-
ber needed to treat larger.
Third, patient preferences must be considered. One
study of 1025 consecutive patients presenting to 19 general
practices in New Zealand found that adding the question to
depression screening “Is this something for which you would
like help?” markedly decreased the number of false-positive
depression diagnoses.18 Although this study focused on diag-
nosis rather than treatment, it is possible that patients with
subthreshold depression who do not desire treatment for
their symptoms are less likely to benefit.
Fourth, the duration of subthreshold depression and the
context in which it occurs should be considered. For
example, individuals who experience adjustment reactions
to adverse life events often have short-duration depressive
symptoms that resolve without active therapy. Thus, there is
a role for watchful waiting in subthreshold depression of
recent onset. Patients could be asked to monitor their symp-
toms (possibly by completing a home-based PHQ-9 or other
depression scale) and, if they fail to improve within a reason-
able period (eg, 1-3 months), to make a follow-up appoint-
ment. Alternatively, they could be scheduled for a follow-up
telephone call or, with advances in automatedmonitoring, be
prompted to complete a web-based depression scale.
The need to carefully weigh the benefits of treat-
ing individuals who have symptoms but fall short of meet-
ing criteria for major depression is not unique to sub-
threshold depression but is applicable to prediabetes, mild
obesity, statins for primary prevention, and numerous
other health care decisions in individuals with mild dis-
ease. In determining eligibility for the CASPER trial, the
ratio of patients with subthreshold to major depression was
4:1. Before expanding treatment beyond major depression
to the larger number of patients with subthreshold depres-
sion, further research to identify those most likely to benefit
is warranted.
Fifth, further study also is needed to determine whether
antidepressants have any role as an alternate therapy for
subthreshold depression. While antidepressants have
frequently not been better than placebo in randomized
trials of subthreshold depression,8 access to evidence-based
psychological therapies varies across health care settings.
Individual patient preferences for medication vs nonphar-
macological treatments also vary. Limited evidence sug-
gests that antidepressants might be beneficial in patients
with more severe subthreshold depression, such as those
with functional impairment or suicidal ideation.6,17,19 Cur-
rently, evidence is stronger for brief psychological therapies
when a treatment intervention is considered for subthresh-
old depression.
In summary, CASPER provides new evidence that collab-
orative care improves outcomes for at least some patients
with subthreshold depression. A principal component of
treatment in CASPER was behavioral activation. Other brief
psychological therapies such as cognitive behavioral therapy
and problem-solving therapy have also proven effective
in some studies. Accessibility of these psychological treat-
ments can be enhanced by telephone or web-based delivery.
Patients with persistent symptoms, functional impairment,
and a desire for treatment may particularly benefit.
Editorial Opinion
jama.com (Reprinted) JAMA February 21, 2017 Volume 317, Number 7 703
Downloaded From: http://jamanetwork.com/ by a Indiana University School of Medicine User  on 09/26/2017
Copyright 2017 American Medical Association. All rights reserved.
ARTICLE INFORMATION
Author Affiliations: VAHealth Services Research
and Development Service Center for Health
Communication and Information, Regenstrief
Institute, Indianapolis, Indiana; Indiana University
School of Medicine, Indianapolis.
Corresponding Author: Kurt Kroenke, MD,
Regenstrief Institute, Room 221, 1101 W 10th St,
Indianapolis, IN 46202 (kkroenke@regenstrief.org).
Conflict of Interest Disclosures: The author has
completed and submitted the ICMJE Form for
Disclosure of Potential Conflicts of Interest and
none were reported.
REFERENCES
1. Löwe B, Spitzer RL, Williams JB, Mussell M,
Schellberg D, Kroenke K. Depression, anxiety and
somatization in primary care: syndrome overlap
and functional impairment. Gen Hosp Psychiatry.
2008;30(3):191-199.
2. Murray CJ, Atkinson C, Bhalla K, et al; US Burden
of Disease Collaborators. The state of US health,
1990-2010: burden of diseases, injuries, and risk
factors. JAMA. 2013;310(6):591-608.
3. OlfsonM, Blanco C, Marcus SC. Treatment of
adult depression in the United States. JAMA Intern
Med. 2016;176(10):1482-1491.
4. Archer J, Bower P, Gilbody S, et al. Collaborative
care for depression and anxiety problems. Cochrane
Database Syst Rev. 2012;10:CD006525.
5. Reed SJ, Shore KK, Tice JA. Effectiveness and
value of integrating behavioral health into primary
care. JAMA Intern Med. 2016;176(5):691-692.
6. Kroenke K. Minor depression: midway between
major depression and euthymia. Ann Intern Med.
2006;144(7):528-530.
7. Rodríguez MR, Nuevo R, Chatterji S,
Ayuso-Mateos JL. Definitions and factors
associated with subthreshold depressive
conditions: a systematic review. BMC Psychiatry.
2012;12:181.
8. Baumeister H. Inappropriate prescriptions of
antidepressant drugs in patients with subthreshold
to mild depression: time for the evidence to
become practice. J Affect Disord. 2012;139(3):240-
243.
9. Lyness JM, HeoM, Datto CJ, et al. Outcomes of
minor and subsyndromal depression among elderly
patients in primary care settings. Ann Intern Med.
2006;144(7):496-504.
10. Jaffe A, Froom J, Galambos N. Minor
depression and functional impairment. Arch Fam
Med. 1994;3(12):1081-1086.
11. Gilbody S, Lewis H, Adamson J, et al. Effect of
collaborative care vs usual care on depressive
symptoms in older adults with subthreshold
depression: the CASPER randomized clinical trial.
JAMA. doi:10.1001/jama.2017.0130
12. Ekers D, Webster L, Van Straten A, Cuijpers P,
Richards D, Gilbody S. Behavioural activation for
depression: an update of meta-analysis of
effectiveness and sub group analysis. PLoS One.
2014;9(6):e100100.
13. Richards DA, Ekers D, McMillan D, et al. Cost
and outcome of behavioural activation vs cognitive
behavioural therapy for depression (COBRA):
a randomised, controlled, non-inferiority trial. Lancet.
2016;388(10047):871-880.
14. Cape J, Whittington C, Buszewicz M,Wallace P,
Underwood L. Brief psychological therapies for
anxiety and depression in primary care:
meta-analysis andmeta-regression. BMCMed.
2010;8:38.
15. Buntrock C, Ebert DD, Lehr D, et al. Effect of
a web-based guided self-help intervention for
prevention of major depression in adults with
subthreshold depression: a randomized clinical
trial. JAMA. 2016;315(17):1854-1863.
16. Jacob V, Chattopadhyay SK, Sipe TA, Thota AB,
Byard GJ, Chapman DP; Community Preventive
Services Task Force. Economics of collaborative
care for management of depressive disorders:
a community guide systematic review.AmJ PrevMed.
2012;42(5):539-549.
17. Ackermann RT, Williams JW Jr. Rational
treatment choices for non-major depressions in
primary care: an evidence-based review. J Gen
Intern Med. 2002;17(4):293-301.
18. Arroll B, Goodyear-Smith F, Kerse N, Fishman T,
Gunn J. Effect of the addition of a “help” question to
two screening questions on specificity for diagnosis
of depression in general practice: diagnostic validity
study. BMJ. 2005;331(7521):884.
19. Bruce ML, Ten Have TR, Reynolds CF III, et al.
Reducing suicidal ideation and depressive
symptoms in depressed older primary care
patients: a randomized controlled trial. JAMA.
2004;291(9):1081-1091.
Opinion Editorial
704 JAMA February 21, 2017 Volume 317, Number 7 (Reprinted) jama.com
Downloaded From: http://jamanetwork.com/ by a Indiana University School of Medicine User  on 09/26/2017
